UK BROKER RATINGS SUMMARY: BofA Raises Lloyds; Liberum Likes Landsec
UK BROKER RATINGS SUMMARY: BofA Raises Lloyds; Liberum Likes Landsec
Read moreUK BROKER RATINGS SUMMARY: BofA Raises Lloyds; Liberum Likes Landsec
Read more(Sharecast News) - Gene and cell therapy group Oxford Biomedica said on Friday that partner Axovant Gene Therapies had pushed out the start date for its trial into a Parkinson's disease treatment.
Read moreUK DIRECTOR DEALINGS SUMMARY: Liontrust Chiefs Bank GBP1.6 Million
Read moreOxford BioMedica Notes Positive Follow-Up Data From AXO-Lenti-PD
Read moreAnother Manufacturing Suite At Oxford Biomedica's Oxbox Gets Approval
Read moreLONDON BRIEFING: BHP To Increase Stake In Gulf Of Mexico Development
Read moreLONDON MARKET PRE-OPEN: Watches Of Switzerland Ups Full-Year Guidance
Read more(Sharecast News) - Oxford Biomedica said it had received government approval for a fourth manufacturing suite within its Oxbox facility which will be used to develop a potential Covid-19 vaccine.
Read moreOxford Biomedica Burns Bright Amid AstraZeneca Vaccine Deal
Read moreLONDON MARKET OPEN: Stocks Tumble In US Fed's Wake And Ahead Of BoE
Read moreLONDON MARKET PRE-OPEN: Next Raises Full-Year Profit Outlook
Read more(Sharecast News) - Drugs maker Oxford Biomedica, which has partnered with pharma giant AstraZeneca to develop a Covid-19 vaccine, said it expected higher second half revenues to push it to a low-to-single digit full year profit.
Read moreUK Earnings, Trading Statements Calendar - Next 7 Days
Read more(Sharecast News) - Oxford Biomedica shares slid on Wednesday on news that AstraZeneca and Oxford University's Covid-19 vaccine trial has been put on hold, as investors fretted over how this might affect the gene and cell therapy company's supply deal with the UK pharmaceuticals giant.
Read more* AZ reserves production capacity at Oxford Biomedica plant* Deal could be expanded beyond new term of 18 months* AZ's drug, Imfinzi, also wins EU okay for aggressive lung cancer* AZ shares rise 1.5%, Oxford Biomedica up 2% (Adds comment on agreeme...
Read more